Source link : https://www.newshealth.biz/health-news/empagliflozin-sheds-liver-fat-in-people-with-and-without-t2d/
TOPLINE: Empagliflozin appears to reduce liver fat content in individuals with obesity without type 2 diabetes (T2D) and patients with T2D and is a potential therapy against metabolic dysfunction–associated steatotic liver disease (MASLD). METHODOLOGY: MASLD, now the most prevalent chronic liver disease, may affect most people with obesity and T2D. No therapy has been approved, […]
Author : News Health
Publish date : 2024-02-22 06:03:26
Copyright for syndicated content belongs to the linked Source.
Categories